OBJECTIVE: Decreased T-cell reactivity in vitro is strongly associated with progression to AIDS and low CD4+ T-cell numbers. Low T-cell responses in vitro induced by CD3 monoclonal antibody (mAb) are predictive for progression to AIDS independent of low CD4+ T-cell counts and high HIV-1 RNA levels. We developed a whole-blood lymphocyte culture system in which T cells were stimulated by a combination of CD3 and CD28 mAb. Combined stimulation of CD28, a costimulatory molecule, and CD3 considerably enhances T-cell responses in vitro and reduces variation coefficients, which may increase the prognostic power of T-cell responses. DESIGN: A prospective study of HIV-1-infected homosexual men followed for 35 months. METHODS: The predictive value of low T-cell responses to CD3 plus CD28 mAb relative to low CD4+ T-cell counts, high HIV-1 RNA levels and the presence of syncytium-inducing (SI) HIV-1 variants was evaluated longitudinally in 202 HIV-1-infected homosexual men followed for 35 months. RESULTS: In multivariate analysis, decreased T-cell responses at baseline were predictive of development of AIDS, independent of low CD4+ T-cell numbers and high HIV-1 RNA levels. In a time-dependent model, HIV-1 RNA levels lost their predictive value, whereas low T-cell responses, low CD4+ T-cell numbers and the presence of SI HIV-1 variants independently predicted AIDS. CONCLUSIONS: These data demonstrate that combined use of virological and immunological markers may be useful in monitoring disease progression and response to antiretroviral therapy.
OBJECTIVE: Decreased T-cell reactivity in vitro is strongly associated with progression to AIDS and low CD4+ T-cell numbers. Low T-cell responses in vitro induced by CD3 monoclonal antibody (mAb) are predictive for progression to AIDS independent of low CD4+ T-cell counts and high HIV-1 RNA levels. We developed a whole-blood lymphocyte culture system in which T cells were stimulated by a combination of CD3 and CD28 mAb. Combined stimulation of CD28, a costimulatory molecule, and CD3 considerably enhances T-cell responses in vitro and reduces variation coefficients, which may increase the prognostic power of T-cell responses. DESIGN: A prospective study of HIV-1-infected homosexual men followed for 35 months. METHODS: The predictive value of low T-cell responses to CD3 plus CD28 mAb relative to low CD4+ T-cell counts, high HIV-1 RNA levels and the presence of syncytium-inducing (SI) HIV-1 variants was evaluated longitudinally in 202 HIV-1-infected homosexual men followed for 35 months. RESULTS: In multivariate analysis, decreased T-cell responses at baseline were predictive of development of AIDS, independent of low CD4+ T-cell numbers and high HIV-1 RNA levels. In a time-dependent model, HIV-1 RNA levels lost their predictive value, whereas low T-cell responses, low CD4+ T-cell numbers and the presence of SI HIV-1 variants independently predicted AIDS. CONCLUSIONS: These data demonstrate that combined use of virological and immunological markers may be useful in monitoring disease progression and response to antiretroviral therapy.
Authors: H Choremi-Papadopoulou; N Panagiotou; E Samouilidou; F Kontopidou; V Viglis; A Antoniadou; J Kosmidis; T Kordossis Journal: Clin Exp Immunol Date: 2000-03 Impact factor: 4.330
Authors: S Resino; I Galán; A Pérez; J A León; E Seoane; D Gurbindo; M Angeles Muñoz-Fernandez Journal: Clin Exp Immunol Date: 2004-09 Impact factor: 4.330
Authors: Benigno Rodriguez; Hernan Valdez; Christoph G Lange; Robert Asaad; Kathy Medvik; Scott F Sieg Journal: Clin Immunol Date: 2010-05-15 Impact factor: 3.969
Authors: M Paiardini; D Galati; B Cervasi; G Cannavo; L Galluzzi; M Montroni; D Guetard; M Magnani; G Piedimonte; G Silvestri Journal: J Virol Date: 2001-11 Impact factor: 5.103
Authors: Xiaoduan Weng; Elena Priceputu; Pavel Chrobak; Johanne Poudrier; Denis G Kay; Zaher Hanna; Tak W Mak; Paul Jolicoeur Journal: J Virol Date: 2004-05 Impact factor: 5.103
Authors: Sanjay U C Sankatsing; Patrick G Hoggard; Alwin D R Huitema; Rolf W Sparidans; Stephen Kewn; Kristel M L Crommentuyn; Joep M A Lange; Jos H Beijnen; David J Back; Jan M Prins Journal: Clin Pharmacokinet Date: 2004 Impact factor: 6.447